Wolverine Trading, LLC Intellia Therapeutics, Inc. Call Options Transaction History

Wolverine Trading, LLC

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$19.72 - $27.36 $159,732 - $221,616	-8,100 Reduced 17.23%	38,900 $799,000
Q2 2024 Aug 14, 2024	BUY	$20.02 - $27.22 $442,442 - $601,562	22,100 Added 88.76%	47,000 $1.05 Million
Q1 2024 May 15, 2024	SELL	$23.82 - $32.8 $11,910 - $16,400	-500 Reduced 1.97%	24,900 $684,000
Q4 2023 Feb 14, 2024	SELL	$23.16 - $32.34 $32,424 - $45,276	-1,400 Reduced 5.22%	25,400 $774,000
Q3 2023 Nov 15, 2023	BUY	$31.62 - $45.78 $309,876 - $448,644	9,800 Added 57.65%	26,800 $847,000
Q2 2023 Aug 23, 2023	SELL	$34.58 - $46.03 $17,290 - $23,015	-500 Reduced 2.86%	17,000 $693,000
Q1 2023 May 15, 2023	SELL	$33.3 - $44.82 $49,949 - $67,230	-1,500 Reduced 7.89%	17,500 $630,000
Q4 2022 Feb 14, 2023	BUY	$33.21 - $62.69 $23,247 - $43,883	700 Added 3.83%	19,000 $663,000
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $37,744 - $50,190	700 Added 3.98%	18,300 $1.01 Million
Q2 2022 Aug 15, 2022	BUY	$38.49 - $76.21 $153,960 - $304,840	4,000 Added 29.41%	17,600 $923,000
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $157,329 - $321,273	2,700 Added 24.77%	13,600 $982,000
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $191,444 - $262,884	-1,900 Reduced 14.84%	10,900 $1.32 Million
Q3 2021 Nov 12, 2021	SELL	$132.37 - $176.78 $1.99 Million - $2.65 Million	-15,000 Reduced 53.96%	12,800 $1.76 Million
Q2 2021 Aug 06, 2021	BUY	$60.88 - $161.91 $462,688 - $1.23 Million	7,600 Added 37.62%	27,800 $4.22 Million
Q1 2021 May 14, 2021	BUY	$46.59 - $83.68 $941,118 - $1.69 Million	20,200 New	20,200 $1.46 Million

315

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.12B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.